WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, June 16, 2005

Hide?	Set Name	Query	Hit Count
	DB=PGPB; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L9	l7 or L8	9380
☐	L8	L6 and treating adj3 disease	7684
☐	L7	L6 and treating adj3 disorder	5437
☐	L6	phosphatase and human	24072
	DB=USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L5	l2 or L4	3976
☐	L4	L1 and treating adj3 disorder	2794
☐	L3	L1 and treating adj3 disordere	0
☐	L2	L1 and treating disease	1707
☐	L1	phosphatase and human	26530

END OF SEARCH HISTORY

```
FILE 'HOME' ENTERED AT 08:45:50 ON 16 JUN 2005

=> FIL STNGUIDE
=> s phosphatase and human
L1        50764 FILE MEDLINE
L2        25001 FILE CAPLUS
L3        14869 FILE SCISEARCH
L4         4237 FILE LIFESCI
L5        42900 FILE BIOSIS
L6        35604 FILE EMBASE

TOTAL FOR ALL FILES
L7       173375 PHOSPHATASE AND HUMAN

=> s l7 and treat? and (disease or disorder)
TOTAL FOR ALL FILES
L14       14175 L7 AND TREAT? AND (DISEASE OR DISORDER)

=> s l14 not 2004-2005/py
TOTAL FOR ALL FILES
L21       12200 L14 NOT 2004-2005/PY

=> dup rem l21
L22        7538 DUP REM L21 (4662 DUPLICATES REMOVED)

=>
=> d 1-10 ibib abs

L22  ANSWER 1 OF 7538  SCISEARCH  COPYRIGHT (c) 2005 The Thomson Corporation
     on STN
ACCESSION NUMBER:    2004:198859  SCISEARCH Full-text
THE GENUINE ARTICLE: 773VF
TITLE:               Pimecrolimus: A review
AUTHOR:              Gupta A K (Reprint); Chow M
CORPORATE SOURCE:    Suite 6, 490 Wonderland Rd S, London, ON N6K 1L6, Canada
                     (Reprint); Sunnybrook & Womens Coll, Hlth Sci Ctr, Div
                     Dermatol, Toronto, ON, Canada; Univ Toronto, Toronto, ON,
                     Canada; Mediprobe Labs Inc, Toronto, ON, Canada
COUNTRY OF AUTHOR:   Canada
SOURCE:              JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND
                     VENEREOLOGY, (SEP 2006) Vol. 17, No. 5, pp. 493-503.
                     Publisher: BLACKWELL PUBLISHING LTD, 9600 GARSINGTON RD,
                     OXFORD OX4 2DG, OXON, ENGLAND.
                     ISSN: 0926-9959.
DOCUMENT TYPE:       General Review; Journal
LANGUAGE:            English
REFERENCE COUNT:     43
                    *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
AB          Pimecrolimus (SDZ ASM 981), an ascomycin derivative, is one of the new classes of
            immunomodulating macrolactarns and was specifically developed for the treatment of
            inflammatory skin diseases. The interest in pimecrolimus has been substantial because
            of its significant anti-inflammatory activity and immunomodulatory capabilities and
            its low systemic immunosuppressive potential The mechanism of action of pimecrolimus
            is the blockage of T cell activation. Pimecrolimus (like all ascomycins) is an
            immunophilin ligand, which binds specifically to the cytosolic receptor, immunophilin
            macrophilin-12. This pimecrolimus- macrophilin complex effectively inhibits the
            protein phosphatase calcineurin, by preventing calcineurin from dephosphorylating the
            nuclear factor of activated T cells (NF-AT), a transcription factor. This results in
            the blockage of signal transduction pathways in T cells and the inhibition of the
            synthesis of inflammatory cytokines, specifically Th1- and Th2-type cytokines.
            Pimecrolimus has also been shown to prevent the release of cytokines and pro-
            inflammatory mediators from mast cells. Several studies have evaluated the
            effectiveness of pimecrolimus as a treatment for skin diseases. In animal models of
            allergic contact dermatitis, topical pimecrolimus was found to be effective. In human
            studies of allergic contact dermatitis pimecrolimus demonstrated significantly more
            efficacy than the control treatment. As well, the effectiveness of pimecrolimus 0.6%
            cream was comparable to 0.1% betamethasone-17-valerate; however, pimecrolimus was not
            associated with any of the side effects characteristic of a topical steroid. Topical
            application of pimecrolimus is not associated with skin atrophy. Pimecrolimus is
            effective and safe in both children and adults with atopic dermatitis. When
```

pimecrolimus 1% cream has been applied to adult atopics, improvement has been observed as early as the first week, with a 72% reduction in severity after 3 weeks. Pharmacokinetic studies have shown very low blood levels of pimecrolimus following topical application, with no accumulation after repeated applications. Following application of pimecrolimus cream occasional transient irritation may be experienced at the application site. Similar results have also been found in children aged 3 months and older following application of pimecrolimus 1% cream. Topical pimecrolimus in psoriasis appears to exhibit a dose-dependent therapeutic effect under semi-occlusive conditions. Pimecrolimus has an enormous potential as a new treatment of inflammatory skin diseases. It has been shown to be effective in atopic and allergic contact dermatitis, with a favorable adverse-effects profile, which includes little effect on the systemic immune response.

L22 ANSWER 2 OF 7538 MEDLINE on STN
ACCESSION NUMBER: 2003082608 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 12594123
TITLE: Zoledronate treatment in active Paget's disease.
AUTHOR: Chung G; Keen R W
SOURCE: Annals of the rheumatic diseases, (2003 Mar) 62 (3) 275-6. Journal code: 0372355. ISSN: 0003-4967.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: (CASE REPORTS)
Letter
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200304
ENTRY DATE: Entered STN: 20030221
Last Updated on STN: 20030410
Entered Medline: 20030409

L22 ANSWER 3 OF 7538 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2004:26913 BIOSIS Full-text
DOCUMENT NUMBER: PREV200400028085
TITLE: N-acetylcysteine in the treatment of non-alcoholic steatohepatitis.
AUTHOR(S): Pamuk, Gulsum Emel [Reprint Author]; Sonsuz, Abdullah [Reprint Author]
CORPORATE SOURCE: Division of Hepatology, Department of Internal Medicine, Cerrahpapa Medical Faculty, University of Istanbul, Istanbul, Turkey
SOURCE: Journal of Gastroenterology and Hepatology, (October 2003) Vol. 18, No. 10, pp. 1220-1221. print.
CODEN: JGHEEO. ISSN: 0815-9319.
DOCUMENT TYPE: Letter
LANGUAGE: English
ENTRY DATE: Entered STN: 31 Dec 2003
Last Updated on STN: 31 Dec 2003

L22 ANSWER 4 OF 7538 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2003:409031 BIOSIS Full-text
DOCUMENT NUMBER: PREV200300409031
TITLE: Response: Abnormal ALP isoenzyme in children with epilepsy treated with carbamazepine.
AUTHOR(S): Verrotti, Alberto [Reprint Author]; Greco, Rita [Reprint Author]; Latini, Giuseppe; Morgese, Guido; Chiarelli, Francesco [Reprint Author]
CORPORATE SOURCE: Department of Pediatrics, University of Chieti, Chieti, Italy
SOURCE: Epilepsia, (August 2003) Vol. 44, No. 8, pp. 1129. print.
ISSN: 0013-9580 (ISSN print).
DOCUMENT TYPE: Letter
LANGUAGE: English
ENTRY DATE: Entered STN: 3 Sep 2003
Last Updated on STN: 3 Sep 2003

L22 ANSWER 5 OF 7538 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:409030 BIOSIS Full-text
DOCUMENT NUMBER: PREV200300409030
TITLE: Abnormal ALP isoenzyme in children with epilepsy treated with carbamazepine.
AUTHOR(S): Okazaki, Toshio [Reprint Author]; Suzuki, Mitsuyuki; Nagai, Tatsuo [Reprint Author]
CORPORATE SOURCE: Department of Forensic Medicine and Science, Graduate School of Medicine, Kitasato University, Kitasato, Sagamihara-shi, Kanagawa Prefecture, Japan
SOURCE: Epilepsia, (August 2003) Vol. 44, No. 8, pp. 1128. print. ISSN: 0013-9580 (ISSN print).
DOCUMENT TYPE: Letter
LANGUAGE: English
ENTRY DATE: Entered STN: 3 Sep 2003
Last Updated on STN: 3 Sep 2003

L22 ANSWER 6 OF 7538 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2003:421557 BIOSIS Full-text
DOCUMENT NUMBER: PREV200300421557
TITLE: Glipizide treatment with short-term alcohol abuse resulting in subfulminant hepatic failure.
AUTHOR(S): Ilario, Marius John-Marc; Turyan, Hach Vladimir; Axiotis, Constantine A. [Reprint Author]
CORPORATE SOURCE: Department of Pathology, Health Science Center at Brooklyn, State University of New York, 450 Clarkson Avenue, Box 25, Brooklyn, NY, 11203-2098, USA
axiotismd@aol.com
SOURCE: Virchows Archiv, (July 2003) Vol. 443, No. 1, pp. 104-105. print.
ISSN: 0945-6317.
DOCUMENT TYPE: Letter
LANGUAGE: English
ENTRY DATE: Entered STN: 10 Sep 2003
Last Updated on STN: 10 Sep 2003

L22 ANSWER 7 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2003:942767 CAPLUS Full-text
DOCUMENT NUMBER: 140:40262
TITLE: Genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics
INVENTOR(S): Nevins, Joseph; West, Mike; Goldschmidt, Pascal
PATENT ASSIGNEE(S): Duke University, USA
SOURCE: PCT Int. Appl., 408 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091391	A2	20031106	WO 2002-XB38221	20021112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003091391	A2	20031106	WO 2002-US38221	20021112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-374547P P 20020423
US 2002-420784P P 20021024
US 2002-421043P P 20021025
US 2002-424680P P 20021108
WO 2002-US38221 A 20021112

AB Genes whose expression is correlated with an determinant of an atherosclerotic phenotype are provided. Also provided are methods of using the subject atherosclerotic determinant genes in diagnosis and treatment methods, as well as drug screening methods. In addition, reagents and kits thereof that find use in practicing the subject methods are provided. Also provided are methods of determining whether a gene is correlated with a disease phenotype, where correlation is determined using a Bayesian anal. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L22 ANSWER 8 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:2697 CAPLUS Full-text
DOCUMENT NUMBER: 140:53403
TITLE: Methods of using benzothiophenone derivatives to treat cancer or inflammation
INVENTOR(S): Zhang, Zaihui; Daynard, Timothy S.; Kalmar, Gabriel Bela
PATENT ASSIGNEE(S): Kinetek Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000314	A1	20031231	WO 2003-CA921	20030618

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-390589P P 20020621
OTHER SOURCE(S): MARPAT 140:53403
AB This invention is directed to the use of certain benzothiophenone derivs. in treating hyperproliferative disorders, e.g., cancer, inflammation, etc. in a mammal. Of particular interest are hyperproliferative disorders associated with cellular modulation of protein phosphorylation states, i.e.. altered activity of phosphorylation modifying enzyme(s), e.g. protein kinases and protein phosphatases . In one aspect of the invention, compds. and pharmaceutical compns. of the invention are used to inhibit the activity of PTPN12 and PTPN2; these enzymes have been associated with alterations in the phosphorylation state of cellular proteins.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 9 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:1006684 CAPLUS Full-text
DOCUMENT NUMBER: 140:53443
TITLE: Methods and systems for management of Alzheimer's disease
INVENTOR(S): Shalev, Alon
PATENT ASSIGNEE(S): Brainsgate Ltd., Israel
SOURCE: PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003105658	A2	20031224	WO 2003-IL508	20030613

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-388931P P 20020614
US 2002-294310 A 20021114

AB A method is provided for the treatment of Alzheimer's disease (AD). The method includes stimulating a sphenopalatine ganglion (SPG) of a subject so that the concentration of a substance in a brain of the subject changes.

L22 ANSWER 10 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:855798 CAPLUS Full-text
DOCUMENT NUMBER: 139:333135
TITLE: Combination therapy including a PPAR α/γ dual agonist, and use in the treatment of hyperglycemia, lipid disorders, and obesity in patients with type 2 diabetes or related disorders
INVENTOR(S): Moller, David E.; Wright, Samuel D.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003088962	A1	20031030	WO 2003-US11896	20030415

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-373091P P 20020416
US 2002-387031P P 20020607

AB The invention provides pharmaceutical compns. comprising a combination of a first drug which is a PPARα/γ dual agonist and a second drug selected from (1) a cholesterol absorption inhibitor, (2) an HMG-CoA reductase inhibitor, (3) a bile acid sequestrant, (4) nicotinyl alc., nicotinic acid, or a salt thereof, (5) a PPARα agonist, (6) a phenolic antioxidant, (7) an acyl CoA-cholesterol acyltransferase (ACAT) inhibitor, and (8) a cholesterol ester transfer protein (CETP) inhibitor, including pharmaceutically acceptable salts of one or more of the active ingredients, and a pharmaceutically acceptable carrier. Such combinations are useful for treating hyperglycemia, lipid disorders , and obesity in patients who have type 2 diabetes, metabolic syndrome, insulin resistance, and impaired glucose tolerance.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 11-20 ibib abs

L22 ANSWER 11 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:737908 CAPLUS Full-text

DOCUMENT NUMBER: 139:256390
TITLE: Transcriptional regulation of protein tyrosine phosphatase PTP-1B gene and its use for drug screening and therapy for diabetes and obesity
INVENTOR(S): Fukada, Toshiyuki
PATENT ASSIGNEE(S): Cold Spring Harbor Laboratory, USA; Tonks, Nicholas K.
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003076634	A2	20030918	WO 2003-EP2552		20030312
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2003223975	A1	20031204	US 2003-388215		20030311
PRIORITY APPLN. INFO.:			US 2002-363787P	P	20020312
			US 2002-435587P	P	20021220
			US 2003-388215	A	20030311

AB Compns. and methods relating to PTP1B associated disorders are provided, based on the discovery that a Y-box protein binding site is present as a transcription enhancer sequence in the promoter region situated upstream (i. e., 5' to) of the human PTP1B gene. This site, situated at nucleotides -155 through -132 of the human PTP1B gene, mediates specific binding interactions with the YB-1 transcription regulatory factor, a member of the Y-box family of proteins. YB-1-targeted antisense constructs reduced PTP1B expression levels, providing an alternative to PTP1B active-site directed regulation of PTP1B activity. Increased phosphorylation of insulin receptor was observed in Rat1 cells that were transfected with YB-1 antisense RNA. The invention claims nucleic acid sequences for Y box protein binding site and for transcription factor YB-1. The invention also claims protein sequences for YB-1. The invention further claims methods for use of transcriptional regulation of human PTP-1 gene for screening drugs and for therapeutic treatment of diabetes and obesity. The invention includes use of reporter genes for measuring PTP-1B enhancer activity, antibodies to the Y-box protein, methods for identifying agents that impair binding of a Y-box protein to a PTP-1B gene promoter Y box, and methods for measuring cellular responses to insulin and leptin.

L22 ANSWER 12 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:678608 CAPLUS Full-text
DOCUMENT NUMBER: 139:219271
TITLE: Modification of defensins and their use in modulating immune response and antimicrobial activity
INVENTOR(S): Moss, Joel; Hirayama, Toshiya; Wada, Akiharo; Levine, Rodney L.; Paone, Gregorino
PATENT ASSIGNEE(S): The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, USA; Nagasaki University
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070176	A2	20030828	WO 2003-US4649	20030218
WO 2003070176	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2002-358504P P 20020219
AB This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. In one embodiment, compns. including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. In one embodiment, a method is provided for modulating an antimicrobial activity. In another embodiment, a method if provided for inhibiting a cytotoxic activity. Also disclosed are methods for treating diseases in a subject that are associated with an immune response, such as inflammatory and pulmonary diseases, using the disclosed modified defensin polypeptides.

L22 ANSWER 13 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:634041 CAPLUS Full-text
DOCUMENT NUMBER: 139:173802
TITLE: KDR-associated phosphatase as target for screening of angiogenesis modulators for therapeutic use
INVENTOR(S): Peters, Kevin Gene
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003067220	A2	20030814	WO 2003-US4029	20030207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003158083	A1	20030821	US 2002-327414	20021220

PRIORITY APPLN. INFO.: US 2002-355125P P 20020208
AB KDR-associated phosphatase is useful as a target to screen for agents useful for the treatment of angiogenesis mediated disorders.

L22 ANSWER 14 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:633897 CAPLUS Full-text
DOCUMENT NUMBER: 139:178697
TITLE: Screening of human monoclonal antibodies against cell surface coreceptor of HIV for diagnosis and therapy
INVENTOR(S): Hua, Shaobing; Pauling, Michelle H.; Zhu, Li
PATENT ASSIGNEE(S): Genetastix Corporation, USA
SOURCE: PCT Int. Appl., 150 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003066830 A2 20030814 WO 2003-US3763 20030207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003165988 A1 20030904 US 2002-71866 20020208
PRIORITY APPLN. INFO.: US 2002-71866 A1 20020208
US 2002-133978 A1 20020425

AB Methods are provided for efficient, high throughput screening of antibody libraries against protein targets, especially membrane proteins. In particular, methods are provided for screening a fully human antibody library against membrane proteins such as chemokine receptors in yeast. More particularly, a library of human single chain antibodies is screened against peptide fragments derived from extracellular domains of human CXCR4 and CCR5 resp. and high affinity monoclonal antibodies against CXCR4 and CCR5 are selected. The antibodies can be used as prophylactics or therapeutics to prevent and treat HIV infection, cancer and other diseases or conditions, as well as for screening drugs and diagnosing diseases or conditions associated with interactions with membrane proteins.

L22 ANSWER 15 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:633497 CAPLUS Full-text
DOCUMENT NUMBER: 139:174286
TITLE: Use of GLP-1 compound for treatment of critically ill patients
INVENTOR(S): Knudsen, Lotte Bjerre; Selmer, Johan; Hansen, Kristian Tage
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066084	A1	20030814	WO 2003-DK61	20030131
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003199445	A1	20031023	US 2003-359324	20030206
PRIORITY APPLN. INFO.:			DK 2002-184	A 20020207
			US 2002-359834P	P 20020226

AB Use of medicament for life saving treatment of critically ill patients SIRS patients, and method of treatment. The medicament comprises a GLP-1 compound which effectively controls the blood glucose level.
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 16 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:590947 CAPLUS Full-text
DOCUMENT NUMBER: 139:148004
TITLE: Digenic mutations of PPARγ and PPP1R3A associated with severe insulin resistance and type 2 diabetes and their use in the diagnosis and treatment of diabetes
INVENTOR(S): Barroso, Ines; Schafer, Alan J.; O'Rahilly, Stephen

O.; Waraham, Nicholas J.
PATENT ASSIGNEE(S): Incyte Genomics, Inc., USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003061583 A2		20030731	WO 2003-US1625	20030117

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR

PRIORITY APPLN. INFO.: US 2002-PV350405 20020118

AB The invention provides mutated genes for peroxisome proliferator-activated receptor gamma (PPARγ) and the glycogen-associated regulatory subunit of protein phosphatase-1 (PPP1R3A), PPARγFS and PPP1R3AFS, resp., and polynucleotides and proteins of PPARγFS and PPP1R3AFS that are expressed in diabetes. In particular, frameshift/premature stop mutations in two unlinked genes, PPARγ and PPP1R3A, which are key regulators of lipid metabolism (adipocyte differentiation) and glycogen synthesis (muscle /liver mode of glycogen storage) resp., are found in type II diabetes patients with severe insulin resistance of two families. Specifically, the frameshift/premature stop mutation (A553AAAiT)fs.185(stop 186) in PPARγ results in a mutation of K = lysine to M = methionine at amino acid position 185 of PPARγ within the second zinc-finger (Zn) of the DNA-binding domain (DBD) together with a mutation of S = serine to stop codon (X) at position 186 of PPARγ. And the frameshift/premature stop mutation (C1984AG)fs.662(stop 668) in PPP1R3A results in mutation of an N = asparagine to stop codon at amino acid position 668 of PPP1R3A. The family pedigree shows the concordance of features related to severe insulin resistance and type 2 diabetes and the presence of PPARγ and PPP1R3A mutations. These mutations are confirmed at the protein level by related protein activity assays. Also disclosed are the summaries of clin. and biochem. characteristics of the frameshift mutation carriers for both PPARγFS and PPP1R3AFS in both family members. Thus, a model of interactions among genes that may underlie common human metabolic disorders such as type 2 diabetes is suggested. It also provides for the use of the DNA mutation, the protein, a polynucleotide encoding the protein, and antibodies that specifically bind the protein in various methods to diagnose, stage, treat, or monitor the treatment of diabetes.

L22 ANSWER 17 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:551645 CAPLUS Full-text
DOCUMENT NUMBER: 139:80300
TITLE: Sequences of a human phosphatidic acid phosphatase 2C sequence homolog and uses in diagnosis, therapy and drug screening
INVENTOR(S): Zhu, Zhimin
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057870	A1	20030717	WO 2003-EP55	20030107

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-344798P P 20020107

AB The invention provides protein and cDNA sequences of a novel human phosphatidic acid phosphatase 2C sequence homolog. The invention also provides reagents and methods of regulating a human phosphatidic acid phosphatase 2C sequence homolog. Reagents that regulate human phosphatidic acid phosphatase 2 and reagents which bind to human phosphatidic acid phosphatase 2 gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including cancer, CNS disorders, and COPD.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 18 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:434595 CAPLUS Full-text

DOCUMENT NUMBER: 139:32331

TITLE: Protein-protein interactions involved in signaling by transforming growth factor-β or TGFβ family members and uses thereof

INVENTOR(S): Legrain, Pierre; Gauthier, Jean-Michel; Colland, Frederic; Jacq, Xavier

PATENT ASSIGNEE(S): Hybrigenics, Fr.

SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045990 A2		20030605	WO 2002-EP13866	20021126

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR

PRIORITY APPLN. INFO.:

US 2001-PV333348	20011126
US 2002-PV384537	20020531
US 2002-PV422471	20021030

AB The present invention relates to protein-protein interactions involved in transforming growth factor-β (TGFβ) disorders and/or diseases. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, Selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins, and pharmaceutical compns. that are capable of modulating the protein-protein interactions. The invention claims polynucleotide and polypeptide sequences for SID® proteins. Some examples show effects of siRNA downregulation or overexpression of SID proteins on TGFβ- and bone morphogenetic protein-dependent reporter activity.

L22 ANSWER 19 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:417966 CAPLUS Full-text

DOCUMENT NUMBER: 139:5611

TITLE: Mkk3b protein for screening modulators of lymphocyte activation and diagnosing/prognosing/treating disorders associated with lymphocyte dysfunction

INVENTOR(S): Fu, Alan C.; Wu, Jun; Liao, Charlene X.; Mancebo, Helena

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003044529	A1	20030530	WO 2002-US36881	20021118

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-332441P P 20011116

AB The present invention provides compns. and methods for modulating lymphocyte activation. Nucleic acids encoding proteins and proteins so encoded which are capable of modulating lymphocyte activation are provided. Compns. and methods for the treatment of disorders related to lymphocyte dysfunction or dysregulation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compns. and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating lymphocyte activation.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 20 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:335288 CAPLUS Full-text
DOCUMENT NUMBER: 138:349758
TITLE: DNA sequence of promoter for human sphingosine kinase 1 and uses
INVENTOR(S): Kohama, Takafumi; Sugiura, Masako
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035871	A1	20030501	WO 2002-JP10882	20021021

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2003199590	A2	20030715	JP 2002-307956	20021023

PRIORITY APPLN. INFO.: JP 2001-325402 A 20011023

AB This invention provides DNA sequence of promoter for human sphingosine kinase 1. The expression level of reporter gene was enhanced when the expression was regulated under sphingosine kinase 1 promoter. The promoter provided in this invention can be used for diagnosis, treatment and screening the drugs for arteriosclerosis, diabetes, thrombosis, inflammation, immunopathy, allergy, cancer and cancer metastasis.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y